Use of metformin in the preparation of a drug for treating learning and memory dysfunction caused by schizophrenia with normal glycolipid metabolism

Abstract

This invention provides the application of metformin in the preparation of a drug for treating learning and memory deficits caused by schizophrenia with normal glucose and lipid metabolism, belonging to the field of pharmaceutical technology. This invention discovers that metformin, under conditions of normal glucose and lipid metabolism, can effectively reduce neuronal apoptosis and neuroinflammatory damage in the prefrontal cortex of the brain in schizophrenia patients, thereby improving their learning and memory deficits. This invention further provides that the molecular target of metformin in repairing prefrontal cortex damage in schizophrenia is CTSS, and that it can downregulate the expression level of CTSS in the prefrontal cortex. The metformin described in this invention represents a repurposing of an existing drug, shortening drug development time and costs, and providing an effective drug treatment for learning and memory deficits caused by schizophrenia with normal glucose and lipid metabolism.

Images